Skip to main content

Low-Carb Breakfast Aids Glucose Measures With Diabetes

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

THURSDAY, June 22, 2023 -- A low-carbohydrate (LC) breakfast is associated with improved glucose measures among individuals with type 2 diabetes (T2D), according to a study published online May 29 in the American Journal of Clinical Nutrition.

Barbara F. Oliveira, Ph.D., from University of British Columbia in Kelowna, Canada, and colleagues investigated if an LC breakfast (∼465 kcal: 25 g protein, 8 g carbohydrates, and 37 g fat) could improve glucose control in people with T2D when compared to a low-fat (LF) control breakfast (∼450 kcal: 20 g protein, 56 g carbohydrates, and 15 g fat). The analysis included 121 participants randomly assigned to LC or LF breakfast for three months.

The researchers found that hemoglobin A1C (HbA1c) was reduced (−0.3 percent) after 12 weeks of an LC breakfast. However, the between-group difference in HbA1c was of borderline statistical significance (−0.2; 95 percent confidence interval, −0.4 to 0.0; P = 0.06). In the LC group, self-reported total daily energy (−242 kcal) and carbohydrate (−73 g) intake were lower but the significance of this difference is unclear. Significant differences were seen for mean and maximum glucose, area under the curve, glycemic variability, standard deviation, and time above range in the LC group, while time in the range was significantly higher versus the LF group.

"Advice and guidance to consume a LC breakfast appears to be a simple dietary strategy to reduce overall energy and carbohydrate intake and improve several continuous glucose monitoring variables," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted June 2023

Read this next

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...

Peanut Consumption Starting in Infancy Provides Lasting Tolerance

THURSDAY, May 30, 2024 -- Peanut consumption starting in infancy and continuing to age 5 years provides lasting tolerance into adolescence, according to a study published in the...

Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation

WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.